Treatment of GBM cell lines with the competitive TG2 inhibitor monodansylcadaverine (MDC) or the selective small molecule irreversible TG2 inhibitors, KCA075 or KCC009, in combination with carmustine, enhanced cell death. This evidence concerns the gene TGM2 and glioblastoma.